Eos SENOLYTIX to present mitochondria-targeted geropeptide at Berlin mitochondria congress

Edited by Samael A. Tejada, Founder & Editor-in-Chief

A Houston biotech is taking its mitochondria-targeted anti-aging drug to the biggest stage in the field. Eos SENOLYTIX announced September 22 that founder and CEO Dr. Kevin Slawin will deliver the industry keynote at the 17th World Congress on Targeting Mitochondria in Berlin (October 21–23) — following the academic keynote by Dr. Hazel Szeto, the discoverer of SS-31/elamipretide — with a joint panel on the path from mitochondrial discovery to approved therapy.

The drug

The lead candidate, PTC-2105, is a proprietary geropeptide designed to modulate mitochondrial function and selectively clear senescent cells — the worn-out cells that accumulate with age. Initial targets: sarcopenia and sarcopenic obesity. The company also expects to close its merger with Pulmatrix, Inc. in Q4 2026.

Why the venue matters

The World Congress on Targeting Mitochondria is the field's flagship industry-academic meeting. A keynote slot — especially paired with Szeto, whose peptide just won FDA approval — signals the company wants to be seen as the next chapter of mitochondria-targeted medicine.

The evidence caveat

This is a company announcement, not data. The therapeutic claims for PTC-2105 are preclinical/clinical-stage. Keynotes don't treat patients — trials do. Watch for actual data, not stage time.

Where the evidence stands

• Established: The keynote announcement and merger timeline are company disclosures.
• Preliminary: PTC-2105's therapeutic claims are preclinical/clinical-stage.
• Contested: Whether mitochondria-targeted geropeptides will work in humans is unproven.
• Absent: No published human efficacy data for PTC-2105.